Anocca Funding Round

5/31/2023

Venture Equity

$36,580,000

Undisclosed

The company intends to use the funds to further develop its unique process that enables discovery and manufacture of cell therapies for cancer on an industrial scale, and to progress its first products into clinical trials. "In recent years, we have made great progress in automating our research platform. In addition, our large-scale and precise analytical methods have allowed us to generate additional data that strengthens the first products that will enter clinical trials. The capital injection will fund the continued expansion of Anocca's research, development, and manufacturing capabilities as well as the start of a first clinical trial which is planned to be initiated in 2024

Private & Independent

Biopharmaceutical

Forskargatan 20C
Södertälje, 151 36
SE

Anocca is a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity. Anocca's technologies enable the highly precise and efficient analysis of T-cell biology required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas. With a focus on delivering TCR-modified T-cell therapies (TCR-T) in oncology, Anocca is rapidly progressing a pipeline of novel T-cell therapies towards clinical trials utilizing our own manufacturing capabilities.